Skip to main content
Advertisement
  • Other Publications
    • EMBO Press
    • EMBO Molecular Medicine (Home)
    • The EMBO Journal
    • EMBO reports
    • Molecular Systems Biology
    • Life Science Alliance
Login

   

Search

Advanced Search

Journal

  • Home
  • Latest Online
  • Current Issue
  • Archive
  • Article Collections
  • Subject Collections

Authors & Referees

  • Submit
  • Author Guidelines
  • Aims & Scope
  • Editors & Board
  • Transparent Process
  • Referee Guidelines
  • Bibliometrics
  • Open Access

Info

  • E-Mail Editorial Office
  • Alerts
  • RSS Feeds
  • Reprints & Permissions
  • Advertise & Sponsor
  • Media Partners
  • News & Press
  • Customer Service
  • Home
  • EMBO Molecular Medicine: 9 (11)

Open Access

Transparent Process

Report

Oral administration of pyrophosphate inhibits connective tissue calcification

Dóra Dedinszki, Flóra Szeri, Eszter Kozák, Viola Pomozi, Natália Tőkési, Tamás Róbert Mezei, Kinga Merczel, Emmanuel Letavernier, Ellie Tang, Olivier Le Saux, Tamás Arányi, Koen van de Wetering, View ORCID ProfileAndrás Váradi
DOI 10.15252/emmm.201707532 | Published online 12.07.2017
EMBO Molecular Medicine (2017) 9, 1463-1470
Dóra Dedinszki
Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Flóra Szeri
Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eszter Kozák
Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Budapest, HungaryDepartment of Immunology, ELTE, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viola Pomozi
Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Budapest, HungaryDepartment of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natália Tőkési
Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamás Róbert Mezei
Department of Mathematics and its Applications Central European University, Budapest, HungaryAlfréd Rényi Institute of Mathematics, Hungarian Academy of Sciences, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kinga Merczel
Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmanuel Letavernier
Sorbonne Universités, UPMC Univ Paris 06, UMR S 1155, Paris, FranceINSERM, UMR S 1155, Paris, FrancePhysiology Unit, AP‐HP, Hôpital Tenon, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellie Tang
Sorbonne Universités, UPMC Univ Paris 06, UMR S 1155, Paris, FranceINSERM, UMR S 1155, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Le Saux
Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamás Arányi
Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Budapest, HungaryMITOVASC, CNRS UMR 6015, Inserm U1083, University of Angers, Angers, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koen van de Wetering
Division of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
András Váradi
Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

Author Affiliations

  1. Dóra Dedinszki1,†,
  2. Flóra Szeri1,†,
  3. Eszter Kozák1,2,
  4. Viola Pomozi1,3,
  5. Natália Tőkési1,
  6. Tamás Róbert Mezei4,5,
  7. Kinga Merczel1,
  8. Emmanuel Letavernier6,7,8,
  9. Ellie Tang6,7,
  10. Olivier Le Saux3,
  11. Tamás Arányi1,9,
  12. Koen van de Wetering10,11 and
  13. András Váradi (varadi.andras{at}ttk.mta.hu)*,1
  1. 1Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Budapest, Hungary
  2. 2Department of Immunology, ELTE, Budapest, Hungary
  3. 3Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
  4. 4Department of Mathematics and its Applications Central European University, Budapest, Hungary
  5. 5Alfréd Rényi Institute of Mathematics, Hungarian Academy of Sciences, Budapest, Hungary
  6. 6Sorbonne Universités, UPMC Univ Paris 06, UMR S 1155, Paris, France
  7. 7INSERM, UMR S 1155, Paris, France
  8. 8Physiology Unit, AP‐HP, Hôpital Tenon, Paris, France
  9. 9MITOVASC, CNRS UMR 6015, Inserm U1083, University of Angers, Angers, France
  10. 10Division of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
  11. 11Present Address: Department of Dermatology and Cutaneous Biology, PXE International Center of Excellence in Research and Clinical Care, Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA
  1. ↵*Corresponding author. Tel: +36 203 569135; E‐mail: varadi.andras{at}ttk.mta.hu
  1. ↵† These authors contributed equally to this work

View Abstract
  • Article
  • Figures & Data
  • Transparent Process
Loading

Abstract

Various disorders including pseudoxanthoma elasticum (PXE) and generalized arterial calcification of infancy (GACI), which are caused by inactivating mutations in ABCC6 and ENPP1, respectively, present with extensive tissue calcification due to reduced plasma pyrophosphate (PPi). However, it has always been assumed that the bioavailability of orally administered PPi is negligible. Here, we demonstrate increased PPi concentration in the circulation of humans after oral PPi administration. Furthermore, in mouse models of PXE and GACI, oral PPi provided via drinking water attenuated their ectopic calcification phenotype. Noticeably, provision of drinking water with 0.3 mM PPi to mice heterozygous for inactivating mutations in Enpp1 during pregnancy robustly inhibited ectopic calcification in their Enpp1−/− offspring. Our work shows that orally administered PPi is readily absorbed in humans and mice and inhibits connective tissue calcification in mouse models of PXE and GACI. PPi, which is recognized as safe by the FDA, therefore not only has great potential as an effective and extremely low‐cost treatment for these currently intractable genetic disorders, but also in other conditions involving connective tissue calcification.

Synopsis

Embedded Image

At variance with previous assumptions, orally administered pyrophosphate appears in the circulation in humans and in mice and attenuates connective tissue calcification in mouse models of pseudoxanthoma elasticum (PXE) and generalized arterial calcification of infancy (GACI).

  • Elevation of plasma PPi level in individuals who ingested one dose of Na4PPi, equivalent to 23% of the maximal tolerable daily dose is enough to transiently restore plasma PPi levels.

  • Na4PPi provided in the drinking water in millimolar concentrations inhibited calcification of the dermal sheet of the vibrissae in PXE and in the GACI mice.

  • The inhibitory effect of PPi on the calcification of the arteries was as robust as 75–88% in offspring when heterozygous GACI mothers received 0.3 mM PPi exclusively during pregnacy.

  • Orally taken PPi may represent a simple route to achieve therapeutic solution for treating diseases caused by or accompanied with connective tissue (arterial) calcification.

  • generalized arterial calcification of infancy
  • oral pyrophosphate treatment
  • pseudoxanthoma elasticum
  • soft tissue calcification

EMBO Mol Med (2017) 9: 1463–1470OpenUrlAbstract/FREE Full Text

Introduction

Physiological mineralization is essential for the normal development of vertebrates and restricted to specific sites of the body. In mammals, biominerals predominantly consist of calcium and phosphate, which form hydroxyapatite. Vertebrates have evolved mechanisms permitting crystallization of calcium and phosphate only at specific sites.

Pyrophosphate (PPi) is a central factor in the prevention of the precipitation of calcium and phosphate in soft peripheral tissues (for a recent review see: Orriss et al, 2016). The liver is the most important source of circulatory PPi, via a pathway depending on ABCC6‐mediated ATP release (Jansen et al, 2013, 2014), though the exact molecular mechanism of ATP release and the actual substrate of ABCC6 is not known. Within the liver vasculature, released ATP is rapidly converted into AMP and PPi by the ectoenzyme ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1; Jansen et al, 2014). Inactivating mutations in the genes encoding enzymes involved in PPi homeostasis result in rare hereditary calcification disorders which include pseudoxanthoma elasticum (PXE, OMIM 264800), generalized arterial calcification of infancy (GACI, OMIM 208000), arterial calcification due to CD73 deficiency (ACDC, OMIM 211800), and Hutchinson–Gilford Progeria Syndrome (HGPS, OMIM 176670). Absence of functional ABCC6 results in PXE, a late onset ectopic calcification disorder, with lesions found in the skin, eyes, and cardiovascular system (Bergen et al, 2000; Le Saux et al, 2000; Ringpfeil et al, 2000). Biallelic mutations in ENPP1 cause GACI, a condition that can become life threatening shortly after birth due to massive calcification of the large‐ and medium‐sized arteries (Rutsch et al, 2003). While in PXE plasma PPi concentration is reduced to 40% of normal (Jansen et al, 2014), GACI patients have virtually no PPi in their blood, which explains the severity of the disease (Rutsch et al, 2003). Other gene products are also involved in soft tissue calcification affecting PPi homeostasis, such as ANK, which mediates the intracellular to extracellular channeling of PPi (Ho et al, 2000), though it does not play a role in maintaining plasma PPi.

Because reduced PPi concentrations in the circulation underlie the ectopic calcification disorders PXE and GACI, a logical treatment for these disorders would be PPi supplementation. Due to the necessity to treat patients lifelong, oral administration would be preferred for such a treatment. Phosphatases are abundantly present in the gut (Ferguson et al, 1968); therefore, it has been always claimed that orally administered PPi cannot reach the circulation and therefore is not effective in inhibiting ectopic calcification (Orriss et al, 2016). We have tested this assumption in healthy human individuals and in mouse models reflecting two human hereditary calcification disorders, PXE and GACI.

Results

Uptake of PPi in humans and mice

First, we tested whether orally consumed PPi is absorbed in humans. Healthy human volunteers (fasting) ingested a solution of tetrasodium pyrophosphate (Na4PPi), resulting in a dose of 40, 67, or 98 mg/kg of body weight (43, 72, 110 mM, pH 8.0, respectively). The ingested amounts of Na4PPi correspond to 13–33% of the maximal tolerable daily intake published by the World Health Organization, WHO (http://www.inchem.org/documents/jecfa/jeceval/jec_2259.htm). This resulted in substantially elevated plasma PPi levels (Fig 1A; with individual differences as shown on Fig 1B) when 98 and 67 mg/kg Na4PPi was taken, while the plasma PPi level was increased only moderately in individuals taking 40 mg/kg (Fig 1A). The time needed to get the plasma PPi back to the baseline level was 240 min at dose 67 mg/kg and 360 min at dose 98 mg/kg (Fig 1A). These data indicate a dose‐ and time‐dependent elevation of plasma PPi concentration. From the data presented in Fig 1A, we calculated the following pharmacokinetic parameters: tmax = 36.7 ± 13.2 min, Cmax = 3.9 ± 1.6 μM, t1/2 = 44.7 ± 16.7 min (single exponential decay) when 98 mg Na4PPi per kg body weight was given.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1. Uptake of PPi from drinking water

  1. Oral uptake of tetrasodium pyrophosphate in humans. Volunteers ingested tetrasodium pyrophosphate solutions of 43, 72, 110 mM, pH 8.0, resulting in a dose of 40 mg/kg (n = 10) or 67 mg/kg (n = 10) or 98 mg/kg (n = 9), respectively. Plasma PPi levels were determined before (0 min), and 30, 60, 120, 240, and 480 min after ingestion. The insert shows the differences between the basal plasma PPi level (0 min) and that 30, 60, and 120 min after ingestion.

  2. Oral uptake of 98 mg/kg tetrasodium pyrophosphate (n = 9) in human indicating individual differences.

  3. Uptake from the oral cavity (n = 5), from the stomach (n = 5), and from the intestine (n = 5) of C57/BI6 mice after ligating the esophagus and applied oral delivery of 100 μl 50 mM PPi; or the pylorus followed by stomach delivery of 200 μl 50 mM PPi and then ligation of the esophagus; or injecting 200 μl 50 mM PPi into the intestine after ligation of the pylorus. In each experiment, including control (n = 7), blood was collected after 15 min and PPi concentrations were determined.

  4. Time‐course of PPi uptake from the stomach of C57/BI6 mice upon gavage delivery of 200 μl of 50 mM PPi, n = 5–11.

  5. Dose‐dependent PPi uptake from the stomach of C57/BI6 mice upon gavage delivery of 200 μl of PPi of concentration 0 (n = 6), 1 (n = 6), 10 (n = 7), 25 (n = 7), 50 (n = 8), and 100 (n = 6) mM. Blood was collected for PPi assay after 15 min of delivery.

Data information: Data were analyzed by two‐tailed Mann–Whitney nonparametric test. Results are expressed as mean ± SEM.

Next, we investigated whether supplementation via the drinking water increased plasma PPi levels in mice. In preliminary experiments, we found that in half of the animals, plasma PPi did not increase. This is most probably due to “non‐synchronized” drinking by the animals. We therefore directly delivered PPi into the oral cavity, stomach, or small intestine (Fig 1C) and placed ligatures downstream and/or upstream of the site of administration to prevent any transfer of PPi. Unexpectedly, PPi was remarkably well absorbed from all sites tested and we followed the uptake of PPi (50 mM, 200 μl) delivered directly to the stomach over time. PPi was rapidly absorbed from the stomach (Fig 1D) and, as expected, its plasma concentrations depended on the dose given (Fig 1E).

Oral PPi inhibits ectopic calcification in Abcc6−/− mice

Abcc6−/− mice recapitulate human PXE, with calcifying lesions found in skin, eyes, and blood vessels (Gorgels et al, 2005; Klement et al, 2005). A drawback of the Abcc6−/− mouse model is the relatively late onset of the first symptoms, making it less convenient for rapid screening of new treatments. However, cryo‐injury applied to the heart results in calcified lesions within 3–6 days (Doehring et al, 2006), a phenomenon fully dependent on the absence of Abcc6 (Brampton et al, 2014). The lesions showed hydroxyapatite crystal nature as determined by transmission electron microscopy (Aherrahrou, 2003). Next, we determined whether orally administered PPi was able attenuating induced cardiac calcification in PXE mice. PPi provided via the drinking water potently inhibited calcification (PPi was provided in the drinking water a day before the cryo‐injury and continued for 4 days) as shown by the reduced calcified area (Fig 2A, calcium deposits stained by Alizarin Red). The extent of inhibition was dose‐dependent, with maximal inhibition seen at a PPi concentration of 10 mM, though the cardiac lesions in Abcc6−/− mice receiving drinking water with 1mM PPi already contained more than twofold less calcium (Fig 2B).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2. Oral PPi attenuates induced cardiac and spontaneous calcification of vibrissae in Abcc6−/− mice

  • A. Calcification of the heart of Abcc6−/− mice after 4 days of cryo‐injury (drinking water, upper image) or (drinking water with 10 mM PPi, lower image). Ca‐precipitations are indicated by arrows, and calcium deposits were visualized by Alizarin Red staining. Scale bar = 1 mm.

  • B. PPi was provided in 0 (n = 8), 1 (n = 8) or in 10 (n = 8) mM concentrations via the drinking water to Abcc6−/− mice starting a day before cryo‐injury for a total of 4 days. The calcium content of heart tissue was determined by complexometry.

  • C, D Show typical Alizarin Red‐stained sections of an animal of the control group and that of the 10 mM PPi group, respectively. Abcc6−/− mice were kept on 10 mM PPi (in drinking water) starting at an age of 3 weeks (after weaning) until they were 22 weeks old. The control group was drinking tap water. Tissue blocks with the vibrissae were removed, paraffin‐embedded, sectioned, and stained with Alizarin Red for calcium deposits, scale bar = 1 mm.

  • E. The extent of calcification, control (n = 9) and 10 mM PPi (n = 9), was quantified by morphometry as described in the Materials and Methods.

Data information: Data were analyzed by two‐tailed Mann–Whitney nonparametric test. Results are expressed as mean ± SEM.

A hallmark phenotype seen in Abcc6−/− mice is the spontaneous gradual calcification of the connective tissue surrounding the vibrissae (Klement et al, 2005). We found that providing Abcc6−/− mice PPi‐containing drinking water (10 mM) after weaning received for 19 weeks greatly reduced the extent of calcification found in the tissue surrounding the vibrissae. These data show that orally administered PPi not only inhibits the calcification seen after the application of cryo‐injury, but also potently inhibits the spontaneous calcification seen in Abcc6−/− mice (Fig 2C–E).

Oral PPi attenuates calcification in Enpp1−/− (ttw) mice

Tiptoe walking (ttw) mice have an inactivating mutation in Enpp1 (Okawa et al, 1998). Due to the complete absence of Enpp1, these mice have extremely low plasma PPi levels and like GACI patients, which develop extensive calcifications in blood vessels and joints shortly after birth (Nitschke & Rutsch, 2012). Just like Abcc6−/− mice, the Enpp1−/− mice develop extensive calcification of the dermal sheet surrounding the vibrissae. In these animals, this phenotype shows up much earlier than in the PXE mice, however.

Orally administered PPi during pregnancy and breastfeeding followed by oral PPi treatment of the pups, resulted in reduced calcification of the dermal sheet surrounding the vibrissae in the Enpp1−/− mice (see Fig 3A–C). We found that treatment of heterozygous Enpp1+/− mothers during their pregnancy with PPi was critical to inhibit the ectopic calcification seen in their Enpp1−/− offspring: Treating Enpp1−/− pups only after weaning did not attenuate ectopic calcification (Fig 3A). We detected a robust effect in the extent of calcification inhibition in the hind limb arteries and in the renal arteries. When PPi in as low as 0.3 mM concentration was provided during pregnancy, calcification was reduced to 12% of the levels found in the control group (hind limb arteries) and to 25% (renal arteries), that is, resulted in 75–88% inhibition (Fig 3D–I).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3. Prenatal PPi treatment of the Enpp1−/− mice attenuates calcification of the tissue surrounding the vibrissae and the arteries of the hind limbs and kidneys

  • A. Calcium content of the tissue blocks of the vibrissae. The heterozygous mothers and their offspring were kept on tap water until the pups were 30 days old (“control”, n = 11); Group 1: as the control group, but for 9 days on 10 mM PPi solution after weaning at day 21 (n = 8); Group 2: the mothers and the pups were kept on 10 mM PPi during pregnancy, breastfeeding and for 9 days after weaning (n = 7). Group 3: The mothers were kept on 10 mM PPi during pregnancy (n = 9). Group 4: The mothers and the pups were kept on 1 mM PPi during pregnancy, breastfeeding, and for 9 days after weaning (n = 13). Group 5: The mothers were kept on 1 mM PPi during pregnancy (n = 8).

  • B, C Typical Alizarin Red‐stained sections of tissue blocks with the vibrissae of animals of different groups. Scale bar: 1 mm

  • D. Calcification of renal arteries. The Enpp1+/− mothers were kept on tap water (n = 7) or on 0.3 mM PPi (n = 6) during pregnancy. Offspring was kept on tap water for 55 days.

  • E. Calcium content of the hind limb arteries. The heterozygous mothers were kept on tap water (n = 7) or 0.3 mM PPi (n = 6) during pregnancy. Offspring was kept on tap water for 55 days.

  • F, G Typical kidney sections of a 55‐day‐old animal of the control group and of a 55‐day‐old animal from the group of 0.3 mM treatment only during pregnancy. Sections were stained by the Yasue procedure. Scale bar: 200 μm.

  • H, I Typical Alizarin Red‐stained hind limb arteries of a 55‐day‐old animal of the control group and those of a 55‐day‐old animal from the group of 0.3 mM treatment only during pregnancy. Scale bar: 1 mm.

Data information: Data were analyzed by two‐tailed Mann–Whitney nonparametric test. Results are expressed as mean ± SEM.

Discussion

Contrary to the general assumption, we found that PPi has bioavailability in humans and mice when administered orally (Fig 1). The observed transient elevation found in healthy volunteers (Fig 1A) indicates that in both GACI and in PXE patients, PPi levels may be transiently raised to the physiological level when 67 or 98 mg Na4PPi/kg of body weight is taken. Importantly, it has been shown that inhibition of calcification in uremic rats and in PXE mice can be achieved by daily intraperitoneal injections of PPi triggering transient increase in plasma PPi levels (O'Neill et al, 2011; Pomozi et al, 2017). We determined a t1/2 = 44.7 min what is rather similar to that published in rat (34.1 min; O'Neill et al, 2011).

We also demonstrated significant attenuation of calcification in two different well‐characterized mouse models of ectopic calcification disorders, PXE and GACI when the animals were treated with pyrophosphate orally. Furthermore, we demonstrated PPi uptake from the oral cavity and stomach of mice allowing a portion of PPi to escape the rapid hydrolytic decomposition presumably occurring in the intestinal tract.

The unexpected observation that 0.3 mM PPi administration was highly effective if applied exclusively during pregnancy (see Fig 3) is likely due to microcrystal formation in the control‐treated group before birth. These microcrystals might be mostly absent in Enpp1−/− pups from heterozygous mothers receiving PPi during pregnancy and would therefore not be available to accelerate the calcification process after birth. GACI is often already diagnosed prenatally in the third trimester or at birth (Kalal et al, 2012) when the calcification is already present. The results in the Enpp1−/− mice suggest that under these conditions oral PPi may not be effective in stopping the progression of calcification unless it is started earlier.

In summary, oral administration may represent a simple route to achieve therapeutic levels of the physiological, non‐toxic metabolite PPi in the blood circulation. Our data indicate that oral PPi has potential to treat two currently incurable diseases, PXE and GACI. Importantly, oral PPi might have broader applicability and be useful in other conditions involving ectopic calcification, such as hypercholesterolemia (Hoeg et al, 1994), diabetes (Kreines et al, 1985), chronic renal insufficiency (Moe & Chen, 2004), β‐thalassemia (Aessopos et al, 1992), and heterotopic ossification of traumatized muscle (Jackson et al, 2009). The risk of orally administrated PPi to patients is probably negligible as the WHO considers PPi a non‐toxic, physiological, metabolite with a high maximal tolerable daily intake value (MTDI) (http://www.inchem.org/documents/jecfa/jeceval/jec_2259.htm). Moreover, it is extensively used as a food additive, and the Code for Federal Regulation by the FDA states: “This substance is generally recognized as safe when used in accordance with good manufacturing practice” (http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.6787). It is also worth noting that PPi would represent a low‐cost treatment of connective tissue calcification disorders.

Materials and Methods

Human study approval

The human uptake studies were approved by the National Review Board of the Ministry of Health, Hungary (ETT TUKEB). The actual permit based on the above approval has been issued by National Public Health and Medical Officer Service (ÁNTSZ, authorization number: IF‐15816‐4/2016). Informed consent was obtained from each volunteer prior to the study and experiments conformed to the principles of Declaration of Helsinki what is indicated in the above document. All patient samples were handled in anonymized form also approved by the above document.

Animals and animal studies

The RCNS, Hungarian Academy of Sciences Institutional Animal Care and Use Committees, approved the animal studies and were conducted according to national guidelines.

C57BL/6J mice designated as wild type were derived from mice purchased from The Jackson Laboratories. Abcc6−/− mice were generated on 129/Ola background and backcrossed into a C57BL/6J > 10 times. Ttw (Enpp1−/−) mice (Okawa et al, 1998) were bred heterozygous due to the severe phenotype seen in the null animals. Both male and female, age‐matched Abcc6−/−, Enpp1−/−, and wild‐type mice were used. For uptake studies, 15‐week‐old C57/BI6 animals were used. In cryo‐injury calcification experiments, 12‐week‐old Abcc6−/− animals were studied. Calcification of the vibrissae of Abcc6−/− mice was determined in 22‐week‐old animals. Calcification of the vibrissae of Enpp1−/− mice was determined in 30‐day‐old animals. Calcification of the hind limb and kidney arteries of Enpp1−/− mice was quantified in 55‐day‐old animals.

All animals were housed in approved animal facilities at the Research Centre for Natural Sciences, Hungarian Academy of Sciences. Mice were kept under routine laboratory conditions with 12‐hour light–dark cycle with ad libitum access to water and chow. Cryo‐injury was performed as described previously (Brampton et al, 2014).

Oral uptake of tetrasodium pyrophosphate in humans

Nine or ten healthy volunteers (age 24–69, fasting) ingested a tetrasodium pyrophosphate solution containing 40 mg/kg or 67 mg/kg or 98 mg/kg (43, 72, 110 mM, pH 8.0, respectively). The ingested amounts of tetrasodium pyrophosphate correspond to 13–33% of the maximal tolerable daily intake published by the World Health Organization, WHO (http://www.inchem.org/documents/jecfa/jeceval/jec_2259.htm). The duration of ingestion was less than one minute. Blood samples were collected before ingestion (0 min) and 30, 60, 120, 240, 360, and 480 min after from the vena cubiti.

Pyrophosphate and plasma PPi assay

Sodium pyrophosphate tetrabasic decahydrate (BioXtra quality) was purchased from Sigma and used in animal experiments. For human absorption studies, tetrasodium pyrophosphate anhydrous, Code 118 was purchased from ICL Food Specialist (St. Louis, Missouri, USA). Determination of PPi concentration in plasma was performed as described (Jansen et al, 2014). Aliquots from the drinking water during the animal studies were checked for the PPi concentration and found to be stable for at least 4 days. PPi‐containing drinking water was changed every second day.

Ca‐measurement

Hearts of Abcc6−/− mice and the tissue blocks harboring the vibrissae of Enpp1−/− mice were digested in 0.15 N HCl for 48 h, and the calcium content was determined by complexometry using the Stanbio Calcium LiquiColor kit (Boerme, TX, USA) following the manufacturer's instructions.

Calcification of the vibrissae of Abcc6−/− mice was quantified by histochemistry as described (Klement et al, 2005). Tissue blocks with the hair capsules (vibrissae) were removed, paraffin‐embedded, sectioned, and stained with Alizarin Red to visualize calcium deposits. The extent of calcification was quantified by morphometry utilizing image analysis software FIJI (Schindelin et al, 2012). The extent of calcification around the vibrissae was quantified by two investigators in a blinded fashion.

Determination of calcification of arteries in the hind limb of Enpp1−/− mice was performed by Alizarin Red staining as described in Kauffenstein et al (2014). Individual images of the arteries were combined using Hugin‐Panorama photo stitcher (Free Software Foundation, Inc., Boston, MA USA). The resulting images were then processed using ImageMagick (https://www.imagemagick.org).

Kidney tissue sections, 4 μm, were stained by the Yasue procedure as described (Letavernier et al, 2016). Sections were perpendicular to interlobar arteries and 500 μm away from renal hilum. A morphometric analysis was performed (7–13 fields) by using FIJI software (Schindelin et al, 2012). Results are expressed as the ratio of calcified area indexed to the whole kidney tissue area.

Statistical analysis

Data were analyzed by two‐tailed Mann–Whitney nonparametric test. Values are expressed as mean ± standard error of the mean (SEM). A P < 0.05 was considered statistically significant, and the actual P‐values are indicated in the corresponding figures. Animal numbers used for individual datasets varied and are shown in the figures.

The paper explained

Problem

Pyrophosphate (PPi), a natural metabolite, is known to inhibit the pathological calcification of soft tissues including smooth muscle cells of the arteries and several calcification disorders, caused by insufficient levels of PPi. However, it was always assumed that PPi is therapeutically inefficacious when orally taken because its bioavailability is negligible.

Results

Orally given PPi appears in the circulation and substantially increases plasma PPi concentrations to levels that are expected to inhibit the soft tissue mineralization seen in several hereditary ectopic calcification disorders. We further show that calcification is strongly attenuated in mouse models of two inherited calcification disorders, pseudoxanthoma elasticum and generalized arterial calcification of infancy, when PPi was provided in the drinking water.

Impact

Our results suggest that oral PPi has potential as an effective, simple, and low‐cost treatment for patients with conditions involving connective tissue and vascular calcification. The risk of oral administration PPi to patients is probably negligible as it is generally recognized to be safe by FDA.

Author contributions

DD, FS, EK, VP, NT, KM, and ET performed experiments and primary data analysis; TRM analyzed data; EL, OLS, and TA designed experiments and analyzed data; KW designed experiments and involved in evaluating data and writing the paper; AV developed the concept, designed experiments, evaluated data, and wrote the article.

Conflict of interest

D.D., F.Sz., K.vdW., and A.V. filed a patent “Oral pyrophosphate for use in reducing tissue calcification” to the Netherland Patent Office (P32885NL00/RKI).

Expanded View

Acknowledgements

The authors are thankful to Piet Borst for his stimulating skepticism at the beginning, for the valuable advice during the study, and for his critical reading of the manuscript. The fruitful discussions with Drs. Balázs Sarkadi, Gergely Szakács, Krisztina Fülöp, and Sharon Terry are also highly appreciated. The technical help of Györgyi Demeter, Emese Törő, and Zsuzsanna Kaminszky is acknowledged. The work was supported by Hungarian grants OTKA 104227, 114336, and VKSz14‐1‐2015‐0155 to A.V., by PXE International to A.V. and K.vd W., and by NIH HL108249 and GM103341 as well as from the Ingeborg v.F. McKee Fund of the Hawaii Community Foundation (15ADVC‐74403) to OLS.

Funding

PXE International
Ingeborg v.F. McKee Fund 15ADVC‐74403
Hungarians Research Grants OTKA 104227114336
Hungarian Innovation Grants VKSz VKSz14‐1‐2015‐0155
HHS|NIH|National Heart, Lung, and Blood Institute (NHLBI)http://dx.doi.org/10.13039/100000050 HL108249
HHS|NIH|National Institute of General Medical Sciences (NIGMS)http://dx.doi.org/10.13039/100000057 GM103341

References

  1. ↵
    Aessopos A, Savvides P, Stamatelos G, Tassiopoulos T, Kaklamanis P, Fessas P, Rombos L, Karagiorga M (1992) Pseudoxanthoma elasticum‐like skin lesions and angioid streaks in β‐thalassemia. Am J Hematol 41: 159–164
    OpenUrlPubMedWeb of Science
  2. ↵
    Aherrahrou Z (2003) Histological and molecular genetic analysis of mice with genetic predisposition to dystrophic cardiac calcification in response to injury. PhD Dissertation, Faculty of Medicine, University of Lübeck, Germany http://www.zhb.uni-luebeck.de/epubs/ediss2.pdf
  3. ↵
    Bergen AAB, Plomp AS, Schuurman EJ, Terry S, Breuning M, Dauwerse H, Swart J, Kool M, van Soest S, Baas F et al (2000) Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet 25: 228–231
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Brampton C, Aherrahrou Z, Chen LH, Martin L, Bergen AAB, Gorgels TGMF, Erdfdi J, Schunkert H, Szabó Z, Váradi A et al (2014) The level of hepatic ABCC6 expression determines the severity of calcification after cardiac injury. Am J Pathol 184: 159–170
    OpenUrl
  5. ↵
    Doehring LC, Kaczmarek PM, Ehlers EM, Mayer B, Erdmann J, Schunkert H, Aherrahrou Z (2006) Arterial calcification in mice after freeze‐thaw injury. Ann Anat 188: 235–242
    OpenUrlPubMed
  6. ↵
    Ferguson A, Watson WC, Maxwell JD, Fell GS (1968) Alkaline phosphatase levels in normal and diseased small bowel. Gut 9: 96–98
    OpenUrlFREE Full Text
  7. ↵
    Gorgels TGMF, Hu X, Scheffer GL, van der Wal AC, Toonstra J, de Jong PTVM, van Kuppevelt TH, Levelt CN, de Wolf A, Loves WJP et al (2005) Disruption of Abcc6 in the mouse: novel insight in the pathogenesis of pseudoxanthoma elasticum. Hum Mol Genet 14: 1763–1773
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Ho AM, Johnson MD, Kingsley DM (2000) Role of the mouse ank gene in control of tissue calcification and arthritis. Science 289: 265–270
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Hoeg JM, Feuerstein IM, Tucker EE (1994) Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb 14: 1066–1074
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Jackson WM, Aragon AB, Bulken‐Hoover JD, Nesti LJ, Tuan RS (2009) Putative heterotopic ossification progenitor cells derived from traumatized muscle. J Orthop Res 27: 1645–1651
    OpenUrlCrossRefPubMed
  11. ↵
    Jansen RS, Küçükosmanoğlu A, de Haas M, Sapthu S, Otero JA, Hegman IEM, Bergen AAB, Gorgels TGMF, Borst P, van de Wetering K (2013) ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci USA 110: 20206–20211
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Jansen RS, Duijst S, Mahakena S, Sommer D, Szeri F, Váradi A, Plomp A, Bergen AA, Elferink RPJO, Borst P et al (2014) ABCC6‐mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation. Arterioscler Thromb Vasc Biol 34: 1985–1989
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Kalal IG, Seetha D, Panda A, Nitschke Y, Rutsch F (2012) Molecular diagnosis of generalized arterial calcification of infancy (GACI). J Cardiovasc Dis Res 3: 150–154
    OpenUrlPubMed
  14. ↵
    Kauffenstein G, Pizard A, Le Corre Y, Vessiéres E, Grimaud L, Toutain B, Labat C, Mauras Y, Gorgels TG, Bergen AA et al (2014) Disseminated arterial calcification and enhanced myogenic response are associated with Abcc6 deficiency in a mouse model of pseudoxanthoma elasticum. Arterioscler Thromb Vasc Biol 34: 1045–1056
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Klement JF, Matsuzaki Y, Jiang QJ, Terlizzi J, Choi HY, Fujimoto N, Li K, Pulkkinen L, Birk DE, Sundberg JP et al (2005) Targeted ablation of the abcc6 gene results in ectopic mineralization of connective tissues. Mol Cell Biol 25: 8299–8310
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Kreines K, Johnson E, Albrink M, Knatterud GL, Levin ME, Lewitan A, Newberry W, Rose FA (1985) The course of peripheral vascular disease in non‐insulin‐dependent diabetes. Diabetes Care 8: 235–843
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Le Saux O, Urban ZS, Tschuch C, Csiszar K, Bacchelli B, Quaglino D, Pasquali‐Ronchetti I, Pope FM, Richards A, Terry S et al (2000) Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet 25: 223–227
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    Letavernier E, Verrier C, Goussard F, Perez J, Huguet L, Haymann JP, Baud  L, Bazin D, Daudon M (2016) Calcium and Vitamin D have a synergistic role in a rat model of kidney stone disease. Kidney Int 90: 809–817
    OpenUrl
  19. ↵
    Moe SM, Chen NX (2004) Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95: 560–567
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Nitschke Y, Rutsch F (2012) Genetics in arterial calcification: lessons learned from rare diseases. Trends Cardiovasc Med 22: 145–149
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y, Ikegawa S (1998) Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 19: 271–273
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    O'Neill WC, Lomashvili KA, Malluche HH, Faugere MC, Riser BL (2011) Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 79: 512–517
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Orriss IR, Arnett TR, Russell RGG (2016) Pyrophosphate: a key inhibitor of mineralisation. Curr Opin Pharmacol 28: 57–68
    OpenUrlCrossRefPubMed
  24. ↵
    Pomozi V, Brampton C, van de Wetering K, Zoll J, Calio B, Pham K, Owens JB, Mart J, Moisyadi S, Váradi A et al (2017) Pyrophosphate supplementation prevents chronic and acute calcification in ABCC6‐deficient mice. Am J Pathol 187: 1258–1272
    OpenUrl
  25. ↵
    Ringpfeil F, Lebwohl MG, Christiano AM, Uitto J (2000) Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP‐binding cassette (ABC) transporter. Proc Natl Acad Sci USA 97: 6001–6006
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Höhne W, Schauer G, Lehmann M, Roscioli T, Schnabel D et al (2003) Mutations in ENPP1 are associated with ‘idiopathic’ infantile arterial calcification. Nat Genet 34: 379–381
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    Schindelin J, Arganda‐Carreras I, Frise E, Kayning V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B et al (2012) Fiji: an open‐source platform for biological‐image analysis. Nat Methods 9: 676–682
    OpenUrlCrossRefPubMedWeb of Science

This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

  • © 2017 Institute of Enzymology, RCNS, Hungarian Academy of Sciences Published under the terms of the CC BY 4.0 license
View Abstract
Previous Article in this IssueNext Article in this Issue
Back to top

  • PDF
  • Share
  • Export
  • Print
Loading

PDF

Review Process

In this Issue
Volume 9, Issue 11
01 November 2017
EMBO Molecular Medicine: 9 (11)
About the cover
Alert me when this article is cited
Alert me if a correction is posted

Article

  • Article
    • Abstract
    • Synopsis
    • Introduction
    • Results
    • Discussion
    • Materials and Methods
    • Author contributions
    • Conflict of interest
    • Expanded View
    • Acknowledgements
    • References
  • Figures & Data
  • Transparent Process

Related Content

More Reports

  • MET mutation causes muscular dysplasia and arthrogryposis
    Hang Zhou, Chengjie Lian, Tingting Wang, Xiaoming Yang, Caixia Xu, Deying Su, Shuhui Zheng, Xiangyu Huang, Zhiheng Liao, Taifeng Zhou, Xianjian Qiu, Yuyu Chen, Bo Gao, Yongyong Li, Xudong Wang, Guoling You, Qihua Fu, Christina Gurnett, Dongsheng Huang, Peiqiang Su
    EMBO Molecular Medicine : e9709
  • A dual‐AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock‐out mice
    Hanan Al‐Moyed, Andreia P Cepeda, SangYong Jung, Tobias Moser, Sebastian Kügler, Ellen Reisinger
    EMBO Molecular Medicine 11: e9396
  • Comprehensive evaluation of coding region point mutations in microsatellite‐unstable colorectal cancer
    Johanna Kondelin, Kari Salokas, Lilli Saarinen, Kristian Ovaska, Heli Rauanheimo, Roosa‐Maria Plaketti, Jiri Hamberg, Xiaonan Liu, Leena Yadav, Alexandra E Gylfe, Tatiana Cajuso, Ulrika A Hänninen, Kimmo Palin, Heikki Ristolainen, Riku Katainen, Eevi Kaasinen, Tomas Tanskanen, Mervi Aavikko, Minna Taipale, Jussi Taipale, Laura Renkonen‐Sinisalo, Anna Lepistö, Selja Koskensalo, Jan Böhm, Jukka‐Pekka Mecklin, Halit Ongen, Emmanouil T Dermitzakis, Outi Kilpivaara, Pia Vahteristo, Mikko Turunen, Sampsa Hautaniemi, Sari Tuupanen, Auli Karhu, Niko Välimäki, Markku Varjosalo, Esa Pitkänen, Lauri A Aaltonen
    EMBO Molecular Medicine 10: e8552
More Report

Related Articles

Cited By...

Request Permissions

Subject Areas

  • Musculoskeletal System
  • Pharmacology & Drug Discovery

Journal

  • Latest Online
  • Current Issue
  • Archive
  • Focus Pages
  • Bibliometrics
  • E-Mail Editorial Office
  • Privacy Policy

Authors & References

  • Aims & Scope
  • Editors & Board
  • Transparent Process
  • Author Guidelines
  • Referee Guidelines
  • Open Access
  • Submit

Info

  • Alerts
  • RSS Feeds
  • Reprints & Permissions
  • Advertise & Sponsor
  • News & Press
  • Customer Service

EMBO

  • Funding & Awards
  • Events
  • Science Policy
  • Members
  • About EMBO

Online ISSN  1757-4684

Copyright© 2019 EMBO

This website is best viewed using the latest versions of all modern web browsers. Older browsers may not display correctly.